Hepatic injury during doxorubicin therapy.
Six patients with acute lymphoblastic leukemia manifested liver dysfunction related to doxorubicin hydrochloride therapy. Other causes, eg, infection, hepatitis, posttransfusion reaction, and leukemic infiltration were ruled out. There was close correlation between the administration of doxorubicin and the appearance of hepatic dysfunction. Doxorubicin may produce an idiosyncratic reaction and must be considered a drug with potential liver toxicity.
D000293:Adolescent; D000328:Adult; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000209:etiology* / Q000473:pathology; D004317:Doxorubicin / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D009336:Necrosis
D004317:Doxorubicin; D001219:Aspartate Aminotransferases; D001663:Bilirubin